Selumetinib, which blocks MEK1/2-dependent ERK1/2 phosphorylation, and thalidomide, which inactivates the NFkB and TGFβ/SMAD signaling pathway, might pave the way for the restoration of cardiac function in cancer patients [27]. This evidence concerns the gene NFKB1 and cancer.